Agios
Servier, Qiagen to Develop PCR-Based Companion Diagnostic to Identify IDH1-Mutant Leukemia
Qiagen will develop a real-time PCR-based in vitro diagnostic to identify patients eligible for Servier's Tibsovo and investigational IDH1-targeted agents.
Agios Submits sNDA for Tibsovo in IDH1-Mutant Bile Duct Cancer
The submission is based on data from a Phase III study showing that Tibsovo improves PFS for previously treated, IDH1-mutated bile duct cancer patients.
In Brief This Week: Myriad Genetics, Diaceutics, Agios, Precipio, Lantern Pharma, Guardant Health
News items for the week of Jan. 18, 2021.
Agios Sells Oncology Business to Servier for $1.8B Upfront
A range of drugs from Agios' cancer pipeline will be transferred to Servier, including two commercial drugs Tibsovo and Idhifa.
Agios Withdraws Tibsovo EU Marketing Application for IDH1-mutated Refractory AML
The decision comes after EMA's CHMP determined that the submitted evidence was not strong enough to demonstrate the drug's benefit in this setting.
Apr 13, 2020